Dr. Deborah K. Armstrong, MD

Dr. Armstrong practices at Jhu - Oncology in Baltimore, Maryland.

Dr. Armstrong's NPI, 1437113255, was assigned on April 17, 2006. Dr. Armstrong graduated from George Washington University School of Medicine and Health Sciences in 1984. Dr. Armstrong holds Maryland license D36986.

Dr. Armstrong's primary practice is Jhu - Oncology, at 401 N Broadway St, Baltimore, MD 21287 in Baltimore City. The practice phone is (410) 933-7400.

Dr. Armstrong's primary practice is Jhu - Oncology in Baltimore, Maryland. Dr. Armstrong is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Armstrong to 1 more hospital, 2 medical groups and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Armstrong practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Armstrong's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Armstrong is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Armstrong's licenses on file in 3 states: Maryland, Virginia and Pennsylvania.

Dmand AI lists breast cancer, colorectal cancer and lung cancer among the conditions Dr. Armstrong treats.

CMS data shows 167 Medicare services from Dr. Armstrong across 3 procedure codes in 2024, for 103 Medicare patients. Medicare paid $19,055 for them.

CMS counts 103 Medicare patients who saw Dr. Armstrong in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high cholesterol, and 67% have cancer. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Armstrong's median patient age at 69, with 93% women.

In 2024, Dr. Armstrong wrote 84 Medicare Part D claims for 20 patients. 94% of them were for generic drugs. CMS names the drug for 50 of them, across 2 drugs with 11 or more claims each, at $900 in total drug cost. In 2023, CMS named 23 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Armstrong for performance year 2024, reported as part of a group. CMS lists Dr. Armstrong as offering telehealth.

Dmand AI links 149 papers to Dr. Armstrong, published from 2005 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Breast Neoplasms. Dr. Armstrong has published most often in Gynecol Oncol. Dr. Armstrong's most frequent co-authors are Robert E. Bristow, MD, Robert L. Coleman, MD and Ronald D. Alvarez, MD.

Dmand AI links Dr. Armstrong to 15 clinical trials, 5 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Ovarian Epithelial, Brenner Tumor and Fallopian Tube Diseases. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 41 general payments to Dr. Armstrong from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 97% of the total. AstraZeneca Pharmaceuticals LP paid the most, $28,451. It also lists 1 research payment totaling $2,200 in 2020.

Dmand AI lists 5 awards for Dr. Armstrong, most recently America's Top Doctors in 2014. Dr. Armstrong serves on Fred Hutchinson Cancer Research Center University off Washington, Mayo Clinic Ovarian Cancer SPORE and chair 2017-2020 Department of Defense Congressionally Directed Medical Research Program Ovarian Cancer Research Program.

Dr. Armstrong graduated from George Washington University School of Medicine and Health Sciences in 1984. Dr. Armstrong is a member of AACR, ASCO and Society of Gynecologic Oncology.

Dr. Armstrong is in network with 7 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.